Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-W...
Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study
About this item
Full title
Author / Creator
Publisher
Heidelberg: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
Heidelberg: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
BackgroundAlirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-...
Alternative Titles
Full title
Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e9dcd563a087429fb9a1fbbcf68627b5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e9dcd563a087429fb9a1fbbcf68627b5
Other Identifiers
ISSN
2199-1154
E-ISSN
2198-9788
DOI
10.1007/s40801-024-00471-w
